M&A / Deals Regeneron deepens relationship with CytomX, adding up to $2B and eight targets BioSpaceAll told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met.OncologyRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) BioSpace All told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Alnylam hops on AI train with up to $2B Inceptive partnershipNext: Peptide biotech Parabilis targets up to $476M IPO Related Stories M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot pharminent July 14, 2026 M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B pharminent July 14, 2026 M&A / Deals Novartis and Chai Discovery collaborate on antibody identification pharminent July 14, 2026
